公开(公告)号：US09475816B2

公开(公告)日：2016-10-25

申请号：US14426369

申请日：2013-09-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Mingnam Tang

IPC: C07D487/04 ,  C07D519/00 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/437 ,  A61K31/496 ,  C07D487/14 ,  A61K31/4162 ,  A61K31/506

CPC classification number: C07D487/04 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  C07D487/14 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

公开(公告)号：US20150225405A1

公开(公告)日：2015-08-13

申请号：US14426369

申请日：2013-09-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Mingnam Tang

IPC: C07D487/04 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/437 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4162 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  C07D487/14 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中L，R 1，R 2，R 3，R 4，R 5，R 6和R 7在本说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。

公开(公告)号：US09434743B2

公开(公告)日：2016-09-06

申请号：US14378305

申请日：2013-02-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Philip Erickson ,  Jun Feng ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Joanne Miura ,  Sean Murphy ,  Mingnam Tang ,  Huong-Thu Ton-Nu

IPC: C07D498/04 ,  C07D401/04 ,  C07D471/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D487/04 ,  C07D401/14 ,  C07D413/14 ,  C07D231/56 ,  C07D403/10 ,  C07D407/14 ,  C07D413/04 ,  C07D413/10 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06

CPC classification number: C07D498/04 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  C07D231/56 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D407/14 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

公开(公告)号：US20150005232A1

公开(公告)日：2015-01-01

申请号：US14378305

申请日：2013-02-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Philip Erickson ,  Jun Feng ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Joanne Miura ,  Sean Murphy ,  Mingnam Tang ,  Huong-Thu Ton-Nu

IPC: C07D498/04 ,  A61K31/416 ,  A61K45/06 ,  C07D401/04 ,  A61K31/4439 ,  C07D471/04 ,  A61K31/437 ,  A61K31/5383 ,  C07D403/04 ,  A61K31/506 ,  C07D405/04 ,  C07D413/10 ,  A61K31/4245 ,  C07D417/04 ,  A61K31/427 ,  C07D401/14 ,  A61K31/5377 ,  C07D487/04 ,  A61K31/53 ,  C07D231/56

CPC classification number: C07D498/04 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  C07D231/56 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D407/14 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6在本说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。